Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is demonstrating promising outcomes in early patient assessments . Current https://bookmarkhard.com/story21378513/retatrutide-emerging-research-and-potential-therapeutic-roles